Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Rhea-AI Summary
Eton Pharmaceuticals (Nasdaq: ETON), a pharmaceutical company specializing in rare disease treatments, has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025.
The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss the results. Investors can participate via phone using the dial-in numbers (800) 715-9871 or (646) 307-1963 with Conference ID 5899895, or through the webcast available on Eton's investor relations website. Management will address both live questions and emailed inquiries sent to investorrelations@etonpharma.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ETON declined 2.40%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
Dial In: (800) 715-9871 or (646) 307-1963; Conference ID: 5899895
Webcast: Click Here
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals, Inc.
FAQ
When will Eton Pharmaceuticals (ETON) report Q2 2025 earnings?
How can investors participate in Eton Pharmaceuticals' Q2 2025 earnings call?
Where can I find the replay of Eton Pharmaceuticals' Q2 2025 earnings webcast?
Can investors submit questions for Eton Pharmaceuticals' Q2 2025 earnings call?
